Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy.
PMID 41872134 · PMC13039919 · Cell death discovery · 2026 · 8 claims · 8 setups
Prostaglandin-mediated immunosuppressive microenvironment formation is a critical contributor to chemotherapy resistance following cisplatin treatment
-
Full-text index only
Reinvigorating COTL1(high) NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours.
PMID 41912896 · PMC13179135 · Nature cell biology · 2026 · 8 claims · 8 setups
A COTL1-high NK cell subset mediates immune checkpoint blockade responsiveness in tsMHC-I impaired tumours
-
Full-text index only
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
PMID 41912809 · PMC13099643 · Nature medicine · 2026 · 7 claims · 8 setups
Quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab has a safety profile consistent with G/nP alone across dose-escalation and dose-expansion phases
-
Full-text index only
Integrating single-cell and bulk transcriptomes to reveal prognostic and immunological features of ecDNA-related genes in osteosarcoma.
PMID 42047819 · PMC13125642 · Cancer immunology, immunotherapy : CII · 2026 · 7 claims · 8 setups
A novel ecDNA-related Gene Prognostic Score Model (EGPSM) was constructed using an integrated framework of 101 machine learning algorithm combinations and validated in training, testing, and external cohorts.
-
Full-text index only
The Presence of CD11c+ B Cells with Potent Effector Memory Phenotype in Lung Adenocarcinoma Correlates with Overall Patient Survival.
PMID 41686183 · PMC12988592 · Cancer immunology research · 2026 · 7 claims · 7 setups
CD79A is a reliable transcriptomic/protein quantifier of B lymphocytes across differentiation stages, unlike CD19/CD20 whose expression changes upon activation